02 October 2020 : Clinical Research
Sodium-Glucose Cotransporter-2 Inhibitor Immediately Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients
Naro Ohashi1ABCDEF*, Taro Aoki1BCE, Takashi Matsuyama1BCE, Sayaka Ishigaki2BCE, Shinsuke Isobe1BCE, Tomoyuki Fujikura1A, Takuya Hashimoto3ABDE, Daisuke Tsuriya3ABDE, Hiroshi Morita3ABDE, Akihiko Kato2AD, Hideo Yasuda1ACDEDOI: 10.12659/MSM.926086
Med Sci Monit 2020; 26:e926086
Table 2 Comparisons of each parameter before and 6 months after sodium-glucose cotransporter-2 inhibitor administration.
| Before administration | After administration | P-value | |
|---|---|---|---|
| Body weight (kg) | 70.58±12.70 | 68.90±13.13 | <0.01 |
| Body mass index (kg/m) | 27.12±4.20 | 26.44±4.19 | <0.01 |
| Systolic blood pressure (mmHg) | 134.9±12.5 | 137.1±15.0 | 0.45 |
| Diastolic blood pressure (mmHg) | 74.6±11.9 | 77.9±12.0 | 0.077 |
| Heart rate (/min) | 78.3±11.2 | 80.0±11.6 | 0.65 |
| Hemoglobin (g/dL) | 13.73±1.61 | 14.78±1.44 | <0.01 |
| Blood urea nitrogen (mg/dL) | 18.08±6.95 | 19.20±4.59 | 0.38 |
| Cr (mg/dL) | 0.97±0.41 | 0.93±0.36 | 0.31 |
| eGFR (mL/min/1.73 m) | 63.25±24.66 | 63.88±22.95 | 0.67 |
| Hemoglobin A1c (%) | 8.24±1.26 | 8.15±1.26 | 0.70 |
| Low-density lipoprotein cholesterol (mg/dL) | 111.2±29.3 | 119.9±37.2 | 0.12 |
| Triglyceride (mg/dL) | 174.0±118.1 | 181.3±107.8 | 0.64 |
| Uric acid (mg/dL) | 6.13±1.36 | 5.20±1.11 | <0.01 |
| Log urinary albumin/Cr (mg/g) | 1.72±0.88 | 1.88±0.75 | 0.14 |
| Log urinary protein/Cr (g/g) | −0.84±0.63 | −0.80±0.69 | 0.76 |
| Fractional excretion of glucose (%) | 1.46±3.80 | 27.81±19.18 | <0.01 |
| Fractional excretion of uric acid (%) | 5.98±2.59 | 7.71±3.22 | 0.039 |
| eGFR – estimated glomerular filtration rate, Cr – creatinine. | |||